AgraFlora Organics International Inc. AGRA AGFAF disclosed Thursday that Farmako GmbH via its subsidiary Farmako Limited has obtained its Home Office Controlled Drug License.
Farmako Limited received the license in less than one month after the examination by the UK Home Office in December was successfully finalized.
With the new license, Farmako Limited plans to start wholesaling medical cannabis in the UK by the middle of 2020, counting on the imports of Bedrocan products from the Netherlands.
“The UK medicinal cannabis market has been estimated to reach US$1.3 billion by 2024, with up to 1% of the UK’s population expected to be eligible to receive medicinal cannabis prescriptions by 20281,” Katrin Eckmans, CEO of Farmako, said in a statement.
“Obtaining the License is a key milestone for our European business, positioning Farmako Limited as an early leader in the rapidly developing UK medicinal cannabis market.”
AgraFlora expects for the license coupled with broad National Health Service insurance coverage to be the crucial strategic component of its global cannabis revenue-generating trading platform.
Related Links
AgraFlora Organics Receives Health Canada's Research License For Bottling Facility
Analyst: New UK Cannabis Regulations Limit Usage, Call For Additional Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.